ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,3451
0,00%
Bitcoin
69.580,14
0,39%
Brent Oil
79,395
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Evelo Biosciences Inc (EVLO)

  7. Evelo Biosciences Inc (EVLO) Notícias

EVLO

Evelo Biosciences (EVLO)

Evelo Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EVLO
DataHoraFonteTítuloCódigoCompanhia
26/01/202419:30Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EVLOEvelo Biosciences Inc
26/01/202419:29Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
26/01/202419:27Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EVLOEvelo Biosciences Inc
26/01/202419:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
12/12/202309:43Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EVLOEvelo Biosciences Inc
12/12/202309:42Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
01/12/202309:11Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
09/11/202319:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
08/11/202322:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
17/10/202308:00GlobeNewswire Inc.Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisNASDAQ:EVLOEvelo Biosciences Inc
21/08/202318:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
18/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVLOEvelo Biosciences Inc
14/08/202308:30GlobeNewswire Inc.Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
10/08/202317:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:EVLOEvelo Biosciences Inc
18/07/202308:27IH Market NewsTuesday’s Wall Street Highlights: Novartis, BofA, Dollar General, Uber, Masimo and moreNASDAQ:EVLOEvelo Biosciences Inc
12/07/202317:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
12/07/202308:30GlobeNewswire Inc.Evelo Biosciences Closes $25.5 Million Private PlacementNASDAQ:EVLOEvelo Biosciences Inc
10/07/202308:30GlobeNewswire Inc.Evelo Biosciences Announces $25.5 Million Private PlacementNASDAQ:EVLOEvelo Biosciences Inc
29/06/202310:00GlobeNewswire Inc.Evelo Biosciences Announces Reverse Stock Split EffectiveNASDAQ:EVLOEvelo Biosciences Inc
23/06/202317:55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EVLOEvelo Biosciences Inc
12/06/202317:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:EVLOEvelo Biosciences Inc
12/06/202309:22Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:EVLOEvelo Biosciences Inc
16/05/202307:00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:EVLOEvelo Biosciences Inc
10/05/202318:12Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:EVLOEvelo Biosciences Inc
28/04/202317:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:EVLOEvelo Biosciences Inc
28/04/202317:20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:EVLOEvelo Biosciences Inc
18/04/202318:24Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:EVLOEvelo Biosciences Inc
18/04/202318:10Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:EVLOEvelo Biosciences Inc
16/03/202309:30Edgar (US Regulatory)Annual Report (10-k)NASDAQ:EVLOEvelo Biosciences Inc
16/03/202308:00GlobeNewswire Inc.Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EVLO

Seu Histórico Recente

EU
B722T
B722T
BIT
F18242
Vontobel Financial Produ...
BIT
P1HZL0
BNP Paribas Issuance
BIT
UR9E4G
UniCredit Bank
LSE
FUS
BOV
ELET6M
ELETROBRAS PNB
BOV
MGLUN60
MGLUN60 Ex:59,9
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados